Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.


Journal

NPJ genomic medicine
ISSN: 2056-7944
Titre abrégé: NPJ Genom Med
Pays: England
ID NLM: 101685193

Informations de publication

Date de publication:
15 Nov 2021
Historique:
received: 06 05 2021
accepted: 15 10 2021
entrez: 16 11 2021
pubmed: 17 11 2021
medline: 17 11 2021
Statut: epublish

Résumé

Neurofibromatosis type 1 (NF1) is caused by loss-of-function variants in the NF1 gene. Approximately 10% of these variants affect RNA splicing and are either missed by conventional DNA diagnostics or are misinterpreted by in silico splicing predictions. Therefore, a targeted RNAseq-based approach was designed to detect pathogenic RNA splicing and associated pathogenic DNA variants. For this method RNA was extracted from lymphocytes, followed by targeted RNAseq. Next, an in-house developed tool (QURNAs) was used to calculate the enrichment score (ERS) for each splicing event. This method was thoroughly tested using two different patient cohorts with known pathogenic splice-variants in NF1. In both cohorts all 56 normal reference transcript exon splice junctions, 24 previously described and 45 novel non-reference splicing events were detected. Additionally, all expected pathogenic splice-variants were detected. Eleven patients with NF1 symptoms were subsequently tested, three of which have a known NF1 DNA variant with a putative effect on RNA splicing. This effect could be confirmed for all 3. The other eight patients were previously without any molecular confirmation of their NF1-diagnosis. A deep-intronic pathogenic splice variant could now be identified for two of them (25%). These results suggest that targeted RNAseq can be successfully used to detect pathogenic RNA splicing variants in NF1.

Identifiants

pubmed: 34782607
doi: 10.1038/s41525-021-00258-w
pii: 10.1038/s41525-021-00258-w
pmc: PMC8593033
doi:

Types de publication

Journal Article

Langues

eng

Pagination

95

Informations de copyright

© 2021. The Author(s).

Références

Hum Mutat. 2008 Sep;29(9):E173-93
pubmed: 18546366
PLoS Genet. 2011 Nov;7(11):e1002371
pubmed: 22125493
Int J Cancer. 2019 Jul 15;145(2):401-414
pubmed: 30623411
Nat Commun. 2020 May 27;11(1):2523
pubmed: 32461616
Clin Genet. 2006 Jul;70(1):1-13
pubmed: 16813595
Genet Med. 1999 Sep-Oct;1(6):248-53
pubmed: 11258625
Ann Neurol. 1999 Nov;46(5):777-82
pubmed: 10553997
Hum Mutat. 2009 Jan;30(1):107-14
pubmed: 18693280
Neurosci Lett. 1996 Jun 21;211(2):85-8
pubmed: 8830850
Hum Genet. 2017 Jun;136(6):665-677
pubmed: 28349240
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Science. 1990 Jul 13;249(4965):181-6
pubmed: 2134734
Hum Mutat. 2013 Nov;34(11):1510-8
pubmed: 23913538
Breast Cancer Res Treat. 2011 Oct;129(3):971-82
pubmed: 21638052
Hum Mol Genet. 2000 Dec 12;9(20):3055-64
pubmed: 11115850
Hum Mutat. 1996;7(2):172-5
pubmed: 8829638
Hum Mutat. 2012 Aug;33(8):1228-38
pubmed: 22505045
Hum Mutat. 2007 Jun;28(6):599-612
pubmed: 17311297
Hum Mol Genet. 1995 May;4(5):915-20
pubmed: 7633452
Clin Genet. 2014 Apr;85(4):318-27
pubmed: 23656349
Genet Med. 2020 Dec;22(12):2081-2088
pubmed: 32773772
Hum Mutat. 2000;15(1):7-12
pubmed: 10612815
EBioMedicine. 2016 May;7:212-20
pubmed: 27322474
Cell. 1990 Jul 13;62(1):187-92
pubmed: 1694727
Genes (Basel). 2018 Apr 17;9(4):
pubmed: 29673180
Genome Res. 2018 Jan;28(1):100-110
pubmed: 29162642
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nat Struct Mol Biol. 2012 Jun 17;19(7):719-21
pubmed: 22705790
J Mol Diagn. 2011 Mar;13(2):113-22
pubmed: 21354044
Genomics. 1990 Aug;7(4):555-65
pubmed: 2117566
Cancer Res. 1997 Aug 1;57(15):3288-93
pubmed: 9242462
Hum Mol Genet. 2000 Jan 22;9(2):237-47
pubmed: 10607834
RNA Biol. 2012 Jun;9(6):911-23
pubmed: 22617876
Hum Mutat. 2000;15(6):541-55
pubmed: 10862084
J Med Genet. 2007 Feb;44(2):81-8
pubmed: 17105749
Hum Mutat. 2004 Dec;24(6):491-501
pubmed: 15523642
Arch Neurol. 1988 May;45(5):575-8
pubmed: 3128965
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
FEBS Lett. 2002 Jul 3;522(1-3):71-6
pubmed: 12095621

Auteurs

R Koster (R)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

R D Brandão (RD)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
GROW Institute for Developmental Biology and Cancer, Maastricht University Medical Center, Maastricht, The Netherlands.

D Tserpelis (D)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

C E P van Roozendaal (CEP)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

C N van Oosterhoud (CN)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

K B M Claes (KBM)

Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

A D C Paulussen (ADC)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
GROW Institute for Developmental Biology and Cancer, Maastricht University Medical Center, Maastricht, The Netherlands.

M Sinnema (M)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

M Vreeburg (M)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

V van der Schoot (V)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

C T R M Stumpel (CTRM)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

M P G Broen (MPG)

Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.

L Spruijt (L)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

M C J Jongmans (MCJ)

Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

S A J Lesnik Oberstein (SAJ)

Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

A S Plomp (AS)

Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

M Misra-Isrie (M)

Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

F A Duijkers (FA)

Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

M J Louwers (MJ)

Pediatrics, Bernhoven hospital, Uden, The Netherlands.

R Szklarczyk (R)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

K W J Derks (KWJ)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

H G Brunner (HG)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
GROW Institute for Developmental Biology and Cancer, Maastricht University Medical Center, Maastricht, The Netherlands.
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Donders Center for Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands.
MHENS School for Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.

A van den Wijngaard (A)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

M van Geel (M)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
GROW Institute for Developmental Biology and Cancer, Maastricht University Medical Center, Maastricht, The Netherlands.

M J Blok (MJ)

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands. rien.blok@mumc.nl.
GROW Institute for Developmental Biology and Cancer, Maastricht University Medical Center, Maastricht, The Netherlands. rien.blok@mumc.nl.

Classifications MeSH